查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968522

伤口皮肤替代材料市场－全球产业规模、份额、趋势、机会、预测：按应用、最终用户、地区和竞争格局划分，2021-2031年

Wound Skin Substitutes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球伤口皮肤替代品市场预计将从 2025 年的 17.6 亿美元成长到 2031 年的 27.5 亿美元，复合年增长率为 7.72%。

这些替代材料包括生物来源、合成材料和生物合成材料，旨在修復或取代受损的皮肤组织，在治疗糖尿病足溃疡、静脉性腿部溃疡和严重烧烫伤等慢性疾病中发挥至关重要的作用。这些产品透过模拟细胞外基质，促进细胞再生并加速伤口缝合。推动市场扩张的一个主要因素是慢性疾病（尤其是糖尿病）在全球范围内的日益流行，这导致需要有效溃疡管理的患者数量显着增加。例如，根据国际糖尿病联盟 (IDF) 的报告，到 2024 年，全球将有约 5.89 亿成年人患有糖尿病，这为这些治疗药物的广泛应用提供了巨大的基础。

市场概览
预测期 2027-2031
市场规模：2025年 17.6亿美元
市场规模：2031年 27.5亿美元
复合年增长率：2026-2031年 7.72%
成长最快的细分市场 慢性伤口
最大的市场 北美洲

儘管市场具有巨大的成长潜力，但由于这些先进疗法的高昂成本，市场面临许多障碍。严格的报销政策和不同医疗体系之间保险覆盖范围的差异，往往构成经济障碍。这些经济壁垒会限制患者获得必要的医疗干预，并阻碍市场整体成长。

市场驱动因素

慢性文明病（尤其是糖尿病和肥胖症）发生率的上升，是推动伤口皮肤替代物应用的主要动力。这些生理状况往往会损害人体自身的自然癒合过程，导致复杂的糖尿病足溃疡，需要以细胞治疗方法进行治疗。世界卫生组织（WHO）预测，到2024年，全球将有超过10亿人患有肥胖症，而肥胖症与循环功能障碍和伤口癒合延迟之间存在科学关联。如此庞大的患者族群需要利用生物工程皮肤结构来治疗慢性皮肤缺陷。此外，区域统计数据也凸显了代谢性疾病负担的日益恶化。根据英国糖尿病协会2024年5月的报告，英国糖尿病患者人数达到创纪录的560万，这意味着易患严重皮肤併发症的人数正在增加。

同时，组织工程技术的快速发展以及胎盘和羊膜同种异体移植的商业性正在推动市场成长。製造商不断推出具有调节发炎和最大限度减少疤痕的多功能替代产品，促使医疗专业人员放弃传统的伤口敷料。再生医学解决方案的扩展在主要市场参与企业的财务表现中得到了清晰的体现。例如，MiMedx集团于2024年2月公布，其2023财年的年度净销售额为3.215亿美元。这项业绩主要归功于该公司先进创伤护理产品组合的广泛应用。这些财务数据表明，在临床实践中，治疗难癒合伤口的方法正朝着使用生物工程替代疗法的方向发生实际转变。

市场挑战

先进创伤护理产品成本不断上涨，加上复杂的报销体系，对皮肤替代物市场的成长构成重大阻碍。医疗保健系统面临着控製成本的巨大压力，导致这些昂贵的生物来源和生物合成材料的核准标准日益严格。这使得支付方经常采用严格的文件标准和不一致的支付政策，为医疗服务提供者带来财务不确定性。这种经济环境，加上持续存在的高拒付和少付风险，使得医院和专科诊所不愿储备或开立此类治疗药物。

这种限制性环境直接影响市场进入和产品推广。据伤口护理利益相关者相关人员称，提案的2023年地方医保覆盖范围决定可能会削弱约200种细胞和组织衍生产品的创伤护理保险报销合格。此类政策变化限制了医生可选择的临床方案，并阻碍了患者获得可能挽救肢体的治疗。当监管障碍削弱了经济可行性时，创新皮肤替代品的推广速度就会放缓，从而阻碍全球市场的整体获利能力和成长。

市场趋势

在对经济高效的治疗方案和更便捷的患者就医途径的需求推动下，创伤护理服务向门诊机构和门诊手术中心的转移正在显着改变市场格局。医疗服务提供者正在加速伤口管理的去中心化，减少患者长时间住院，转而采用配备携带式自动化再生医学技术的专科诊所。这一趋势简化了低危险环境下的伤口治疗，在维持临床疗效的同时，减轻了医疗系统的经济负担。根据Avita Medical截至2025年1月的财年财报，其季度商业收入约为1,840万美元，较上一季成长30%。这一成长主要得益于该公司即时再生医学设备在不断扩展的治疗环境中的加速部署。

同时，无细胞真皮基质（ADM）和合成支架的应用日益广泛。与传统的细胞疗法相比，这些材料具有明显的优势。与难以保存且有免疫抗原性风险的细胞同种异体移植不同，无细胞异种移植和合成基质能够提供稳定、即用型的支架，促进与活体组织的整合和新生血管形成。这些材料在复杂重组手术中展现的供应可靠性和结构完整性，进一步支撑了这个趋势。财务数据也印证了这项需求。 Integra Life Sciences 2025财年财报显示，其伤口重组板块实现了8.2%的内部成长，这主要得益于DuraSorb和MicroMatrix等生物工程和合成基质产品销售额的低两位数增长。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球伤口皮肤替代市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依应用范围（慢性伤口、急性伤口、其他）
    • 按最终使用者（医院、门诊手术中心、专科诊所等）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美伤口皮肤替代市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲伤口皮肤替代材料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区伤口皮肤替代材料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲伤口皮肤替代材料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲伤口皮肤替代材料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球伤口皮肤替代材料市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Coloplast A/S
  • Smith & Nephew plc
  • MTF Biologics
  • MIMEDX, Inc.
  • AVITA Medical, Inc.
  • MISONIX, Inc.
  • Mallinckrodt Pharmaceuticals
  • Tissue Regenix Ltd
  • Vericel Corporation
  • Integra LifeSciences Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24087

The Global Wound Skin Substitutes Market is projected to expand from USD 1.76 Billion in 2025 to USD 2.75 Billion by 2031, registering a compound annual growth rate of 7.72%. These substitutes encompass biological, synthetic, and biosynthetic materials designed to repair or replace damaged dermal tissue, playing a vital role in treating chronic conditions like diabetic foot ulcers, venous leg ulcers, and severe burns. By mimicking the extracellular matrix, these products promote cellular regeneration and expedite wound closure. A primary factor fueling this market expansion is the escalating global prevalence of chronic diseases, specifically diabetes, which vastly increases the number of patients needing effective ulcer management. For example, the International Diabetes Federation reported that approximately 589 million adults were living with diabetes globally in 2024, providing a significant basis for the increased utilization of these therapeutic agents.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.76 Billion
Market Size 2031USD 2.75 Billion
CAGR 2026-20317.72%
Fastest Growing SegmentChronic wounds
Largest MarketNorth America

Despite this growth potential, the market faces a major hurdle regarding the substantial costs linked to these advanced therapies. Strict reimbursement policies and variable insurance coverage across different healthcare systems frequently establish financial obstacles. These economic barriers restrict patient access to essential medical interventions and potentially obstruct broader market growth.

Market Driver

The rising incidence of chronic lifestyle diseases, particularly diabetes and obesity, serves as a major driver for the adoption of wound skin substitutes. These physiological states often compromise natural healing processes, resulting in complex diabetic foot ulcers that demand cellular-based therapies for successful closure. As per the World Health Organization, over 1 billion people globally were living with obesity in 2024, a condition scientifically associated with compromised circulation and delayed wound regeneration. This vast patient population necessitates the use of bioengineered skin constructs for managing chronic defects. Furthermore, regional statistics underscore the increasing burden of metabolic disorders; according to a May 2024 report by Diabetes UK, the number of individuals living with diabetes in the UK hit a record 5.6 million, signaling a growing demographic prone to serious skin complications.

Simultaneously, the market is propelled by rapid technological progress in tissue engineering and the commercial uptake of placental and amniotic-based allografts. Manufacturers are launching versatile substitutes that modulate inflammation and minimize scarring, prompting healthcare providers to transition away from conventional dressings. This increasing approval of regenerative solutions is evident in the financial results of major industry participants. For instance, MiMedx Group Inc. reported in February 2024 that it achieved full-year net sales of USD 321.5 million for 2023, a performance largely credited to the rising adoption of its advanced wound care portfolio. Such financial figures illustrate a concrete shift toward employing bioengineered substitutes for treating hard-to-heal wounds in clinical environments.

Market Challenge

The elevated cost of advanced wound care products combined with complex reimbursement frameworks poses a significant impediment to the skin substitutes market's growth. Healthcare systems are under immense pressure to control costs, resulting in strict approval criteria for these premium biological and biosynthetic materials. Consequently, payers frequently enforce rigorous documentation standards and inconsistent payment policies, generating financial uncertainty for medical facilities. This economic climate dissuades hospitals and specialized clinics from stocking or prescribing these treatments, as the risk of claim denial or underpayment remains substantial.

This restrictive environment directly affects market accessibility and product usage rates. According to the Alliance of Wound Care Stakeholders, proposed local coverage determinations in 2023 threatened to revoke Medicare reimbursement eligibility for roughly 200 cellular and tissue-based products. Such policy changes constrain the clinical choices available to physicians and restrict patient access to therapies that could potentially save limbs. When regulatory hurdles compromise financial feasibility, the adoption of innovative skin substitutes decelerates, thereby hindering the global market's overall revenue potential and expansion.

Market Trends

The migration of wound care services toward outpatient facilities and ambulatory surgical centers is profoundly reshaping the market landscape, fueled by the demand for cost-efficient treatment delivery and enhanced patient access. Healthcare providers are increasingly decentralizing wound management, shifting away from extended hospital stays in favor of specialized clinics employing portable and automated regenerative technologies. This move facilitates the efficient treatment of defects in lower-acuity settings, alleviating the financial strain on healthcare systems while upholding clinical efficacy. According to Avita Medical's revenue update in January 2025, the company reported commercial revenue of approximately USD 18.4 million for the quarter, marking a 30% increase largely driven by the accelerated adoption of its point-of-care regenerative devices in these growing treatment settings.

Concurrently, there is a rising use of acellular dermal matrices (ADMs) and synthetic scaffolds, which present distinct benefits over conventional cellular-based therapies. Unlike cellular allografts that may pose storage difficulties and immunogenic risks, acellular xenografts and synthetic matrices offer a stable, off-the-shelf scaffold that promotes native tissue integration and neovascularization. This trend is further supported by the supply reliability and consistent structural integrity these materials offer for complex reconstruction cases. This demand is confirmed by financial figures; according to Integra LifeSciences' February 2025 financial results, the company realized an 8.2% organic growth in its Wound Reconstruction segment, bolstered by low-double-digit sales gains in its bioengineered and synthetic matrices such as DuraSorb and MicroMatrix.

Key Market Players

  • Coloplast A/S
  • Smith & Nephew plc
  • MTF Biologics
  • MIMEDX, Inc.
  • AVITA Medical, Inc.
  • MISONIX, Inc.
  • Mallinckrodt Pharmaceuticals
  • Tissue Regenix Ltd
  • Vericel Corporation
  • Integra LifeSciences Corporation

Report Scope

In this report, the Global Wound Skin Substitutes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Wound Skin Substitutes Market, By Application

  • Chronic Wounds
  • Acute Wounds
  • Others

Wound Skin Substitutes Market, By End-User

  • Hospitals
  • Ambulatory surgical Centers
  • Specialty Clinics
  • Others

Wound Skin Substitutes Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Wound Skin Substitutes Market.

Available Customizations:

Global Wound Skin Substitutes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Wound Skin Substitutes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Chronic Wounds, Acute Wounds, Others)
    • 5.2.2. By End-User (Hospitals, Ambulatory surgical Centers, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Wound Skin Substitutes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End-User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Wound Skin Substitutes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End-User
    • 6.3.2. Canada Wound Skin Substitutes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End-User
    • 6.3.3. Mexico Wound Skin Substitutes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End-User

7. Europe Wound Skin Substitutes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End-User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Wound Skin Substitutes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End-User
    • 7.3.2. France Wound Skin Substitutes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End-User
    • 7.3.3. United Kingdom Wound Skin Substitutes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End-User
    • 7.3.4. Italy Wound Skin Substitutes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End-User
    • 7.3.5. Spain Wound Skin Substitutes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End-User

8. Asia Pacific Wound Skin Substitutes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End-User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Wound Skin Substitutes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End-User
    • 8.3.2. India Wound Skin Substitutes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End-User
    • 8.3.3. Japan Wound Skin Substitutes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End-User
    • 8.3.4. South Korea Wound Skin Substitutes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End-User
    • 8.3.5. Australia Wound Skin Substitutes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End-User

9. Middle East & Africa Wound Skin Substitutes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End-User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Wound Skin Substitutes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End-User
    • 9.3.2. UAE Wound Skin Substitutes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End-User
    • 9.3.3. South Africa Wound Skin Substitutes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End-User

10. South America Wound Skin Substitutes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End-User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Wound Skin Substitutes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End-User
    • 10.3.2. Colombia Wound Skin Substitutes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End-User
    • 10.3.3. Argentina Wound Skin Substitutes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Wound Skin Substitutes Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Coloplast A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Smith & Nephew plc
  • 15.3. MTF Biologics
  • 15.4. MIMEDX, Inc.
  • 15.5. AVITA Medical, Inc.
  • 15.6. MISONIX, Inc.
  • 15.7. Mallinckrodt Pharmaceuticals
  • 15.8. Tissue Regenix Ltd
  • 15.9. Vericel Corporation
  • 15.10. Integra LifeSciences Corporation

16. Strategic Recommendations

17. About Us & Disclaimer